Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Ziv-Aflibercept,ZAFL2023-001,2023,USA,MDV,350,68,45,55,27.5,32,78,12,15,25,30,30,40,30,20,10,20,30,35,18,8,5,10,7,22,48,35,FOLFOX,CAPOX,CAPOX,XELOX,5,3,2,40,65,55,15,45,40,60,2
Ziv-Aflibercept,ZAFL2022-002,2022,Germany,Claim Database,420,72,48,52,26.8,28,75,15,12,28,32,28,38,32,18,12,18,32,38,20,10,6,12,8,25,50,40,FOLFOX,FOLFIRI,CAPOX,XELOX,6,4,3,45,70,60,10,50,40,65,3
Ziv-Aflibercept,ZAFL2024-003,2024,Japan,MDV,280,70,42,58,25.5,25,80,10,18,22,35,25,42,28,15,15,22,28,40,15,7,4,9,6,20,45,30,FOLFOX,CAPOX,CAPOX,XELOX,4,2,1,35,60,50,20,40,40,70,2.5
